EMA Recommends Granting a Marketing Authorisation for Relacorilant By Ogkologos - October 2, 2026 248 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with epithelial ovarian, Fallopian tube or primary peritoneal cancer Source RELATED ARTICLESMORE FROM AUTHOR A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research MOST POPULAR FDA Grants Accelerated Approval to Zanubrutinib for Relapsed or Refractory Follicular... March 22, 2024 Study Advances Fertility Preservation Approach for Male Cancer Survivors April 24, 2019 EMA Recommends Extension of Indications for Durvalumab in the Management of... October 25, 2023 Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides... March 25, 2025 Load more HOT NEWS Surgical Technique Helps Keep Breast Cancer Patients from Going Under the... 7 Tips For Keeping The Entire Family Healthy During Flu Season More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer Rapid, Robust and Durable Antitumour Activity of Pralsetinib in Patients with...
